Siemens Healthcare: service element is vital addition to product offering
This article was originally published in Clinica
Having spent Euro11.2bn ($17.5bn) over the last 18 months in buying three major IVDs groups, Siemens Healthcare has managed to gain a broad oversight into the trends and pressures within the global diagnostics sector - in vivo and in vitro.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.